Rhumbline Advisers Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Rhumbline Advisers increased its position in Repligen Co. (NASDAQ:RGEN) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 146,149 shares of the biotechnology company’s stock after acquiring an additional 2,739 shares during the period. Rhumbline Advisers owned about 0.26% of Repligen worth $21,037,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. CWM LLC grew its position in Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 114 shares during the period. Creative Planning boosted its holdings in Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock worth $762,000 after buying an additional 1,259 shares during the period. Blue Trust Inc. lifted its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Raymond James & Associates lifted its stake in Repligen by 49.3% in the 3rd quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock worth $12,244,000 after purchasing an additional 27,158 shares in the last quarter. Finally, Greenleaf Trust purchased a new stake in Repligen in the 3rd quarter worth $226,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $182.91.

Repligen Trading Up 7.9 %

Shares of RGEN stock opened at $162.67 on Friday. The firm has a market cap of $9.11 billion, a P/E ratio of -439.64, a PEG ratio of 4.08 and a beta of 0.99. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm’s 50-day simple moving average is $155.17 and its 200-day simple moving average is $148.81.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. As a group, equities analysts forecast that Repligen Co. will post 1.54 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.